ExoCellular Diagnostics

EDx700™

Hsp70-based liquid biopsy for cancer detection and disease monitoring

The concept of measuring exosomal Hsp70 as a cancer-specific biomarker and its diagnostic potential has been studied in 448 patients covering a range of different cancer settings (head and neck cancer, colorectal cancer, pancreatic cancer, glioblastoma, hematological malignancy, breast cancer, non small cell lung cancer) and the data published in multiple internationally peer-reviewed publications.

References:

  • Breuninger et al., Clinical & Cellular Immunology 2014
  • Gunther et al., Frontiers in Immunology 2015
  • Ostheimer et al., Frontiers in Immunology 2017
  • Werner et al., Cancers 2021
  • Seier et al, Frontiers in Immunology 2022

EDx700™

EDx700™ is an enzyme-linked immunosorbent assay (ELISA) which uses two unique monoclonal antibodies (mAbs) recognizing the membrane form of Heat Shock Protein 70 (Hsp70) to detect circulating levels of exosome-associated Hsp70 in the blood.

Hsp70 has been discovered to be highly expressed on the cell membrane of most blood cancers and solid tumors, but not on normal healthy cells and tissues. Primary and metastatic tumor cells expressing membrane Hsp70 release small extracellular vesicles called exosomes which express Hsp70 into the blood. Exosomes are extracellular vesicles secreted by most cells and play a crucial role in regulating tumor growth, metastasis, and angiogenesis in the process of cancer development. Levels of exosomal Hsp70 measured using this simple blood test can be used to confirm the presence of cancer, even in its early stages, and to monitor therapeutic efficacy and disease recurrence.

EDx700™ has been granted CE marking and In Vitro Diagnostic (IVD) Designation (IVD-D) in the European Union, it is cleared for marketing in the 27 countries in the European Union (plus the United Kingdom).

EDx700™ is expected to gain marketing approval in the United States of America as a Laboratory Diagnostic Test (LDT).

Granted US patent and patents pending.

Standard Biopsy

Time-Intensive Procedure

Localized Sampling of Tissue

Not Easily Obtained

Some Pain/Risk

Invasive

VS

Liquid Biopsy

Quick

Comprehensive Tissue Profile

Easily Obtained

Minimal Pain/Risk

Minimally Invasive